Application of plant-derived small molecules including glycyrrhizic acid as PAD4 inhibitor

By combining glycyrrhizic acid, quercetin and hambasalin as small-molecular PAD4 inhibitors, the problem of poor cell permeability and metabolic stability of PAD4 inhibitors in the prior art is solved, significantly inhibiting the formation of NETs, ​​and achieving the NET Effective treatment of related diseases.

CN119074743APending Publication Date: 2024-12-06GUANGZHOU UNIVERSITY OF CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411031263.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Most of the existing PAD4 inhibitors are peptides, which show high hydrophilicity, cell permeability and poor metabolic stability, making it difficult to effectively inhibit the formation of NETs, ​​resulting in challenges in the treatment of NET-related diseases.

Method used

The combination of glycyrrhizic acid, quercetin and hambasalin was used as a small molecule substance to screen and verify its inhibitory effect on PAD4 enzyme activity, and as an inhibitor of peptidyl arginine deimidase 4, inhibiting neutral particles. The formation of extracellular trapping nets in cells.

Benefits of technology

Glycyrrhizic acid, quercetin and hambasalin significantly inhibit PAD4 enzyme activity, reduce the aggregation of NETs, ​​have good cell permeability and metabolic stability, and are effectively used to treat colitis-related tumors and other NET-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074743A_ABST
    Figure CN119074743A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and provides application of plant-derived small molecules containing glycyrrhizic acid as a peptidyl arginine deiminase 4 (PAD4) inhibitor. Researches show that glycyrrhizic acid, quercetin and wogonin have a remarkable inhibition effect on PAD4 enzyme activity, and further cell model and animal model experiments prove that glycyrrhizic acid can inhibit cells from forming NETs, inhibit expression of PAD4 in colonic tissues of model mice and reduce aggregation of NETs in the colonic tissues, so that the effect of treating tumors related to colitis is achieved. Besides, glycyrrhizic acid, quercetin and wogonin are all micromolecules derived from safe plants, and glycyrrhizic acid is used as a sweetening agent and a flavoring agent to be widely applied to various foods, has no obvious toxic effect on the environment, human bodies and plants, and is high in safety; and compared with most peptide-based PAD inhibitors, the small-molecule inhibitor has better cell permeability and stability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and more specifically, relates to the application of plant-derived small molecules including glycyrrhizic acid as peptidyl arginine deiminase 4 (PAD4) inhibitors. Background Art

[0002] Peptidyl arginine deiminase 4 (PAD4) is a post-translational modification enzyme that can convert arginine residues in proteins into citrulline residues. PAD4 is mainly expressed in granulocytes, mainly neutrophils, and is a key enzyme in NETosis, a programmed cell death mode unique to neutrophils. When neutrophils are stimulated by IL-8, TNF-α, bacterial cell wall components, etc., PAD4 is activated and incorporated into the nucleus, converting the positively charged arginine residues on histones into neutral citrulline residues, greatly weakening the binding force between histones and DNA, thereby promoting chromatin depolymerization, and at the same time, the nuclear membrane and plasma membrane rupture, and the DNA and citrullinated histone 3 (citH3) reticular complexes containing inflammatory mediators such as myeloperoxidase (MPO) and neutrophil elastase (NE) are discharged to the extracellular space, thus forming neutrophil extracellular traps (NETs). Under physiological conditions, the production of NETs can effectively immobilize pathogens and expose them to high concentrations of effector substances, thereby effectively killing them.

[0003] However, like many protective mechanisms, the formation of NETs may be a double-edged sword, as it is involved in the development of a variety of diseases. Many chronic inflammatory and autoimmune diseases, such as inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and chronic obstructive pulmonary disease, have been found to have abnormally increased production of NETs. In colitis, NETs retained in intestinal tissues can activate monocytes in the lamina propria to release TNF-α and IL-1β, and can also release a variety of inflammatory factors such as myeloperoxidase (MPO), elastase (NE), and matrix metalloproteinases (MMPs) to maintain local inflammation and cause persistent tissue damage. During chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), NETs can block the airways and reduce lung function, and can also provide pro-inflammatory stimulation to macrophages, thereby exacerbating inflammation in CF subjects and leading to pulmonary fibrosis. Extracellular histones produced by NETs may also act as DAMPs, releasing cfDNA to induce increased TNF-α mRNA expression, causing inflammation and organ damage, and promoting sepsis. In addition, NETosis is closely related to the pathogenesis of systemic lupus erythematosus, and NETs are an important source of SLE autoantigens. Under normal circumstances, NETs may be degraded in serum. However, patients with systemic lupus erythematosus have autoantibodies against histones and cfDNA, which protect NETs from degradation. PAD4 and histones are released during NETosis. PAD4 is a protein citrullination modification enzyme. In this process, PAD4 citrullinates the released histones. Autoantibodies in the serum of SLE patients preferentially bind to the citrullinated core histones in NETs. At the same time, citrullinated histones produce new autoantibody epitopes, which may stimulate B cells to produce autoantibodies, which may promote the progression of SLE. This is also true for rheumatoid arthritis and small vessel vasculitis. Therefore, inhibiting the formation of NETs is the key to treating these diseases.

[0004] PAD4 is a key enzyme in the formation of NETs. Inhibiting the activity of PAD4 becomes a good strategy for treating these diseases. The development of efficient and specific PAD4 inhibitors is very important for the treatment of these diseases with abnormally increased production of NETs.

[0005] Currently, most PAD4 inhibitors are peptides. However, most peptide-based PAD4 inhibitors show high hydrophilicity, which leads to poor cell permeability and metabolic stability. Therefore, the development of efficient, safe and stable PAD4 inhibitors is of great significance for the treatment of NET-related diseases or PAD4-mediated diseases. Summary of the invention

[0006] The present invention aims to provide a new small molecule PAD4 inhibitor that is safe, efficient, and has good cell permeability and metabolic stability.

[0007] The first object of the present invention is to provide a small molecule substance for use as a peptidyl arginine deiminase 4 inhibitor, wherein the small molecule substance is one or a combination of glycyrrhizic acid, quercetin, and wogonin.

[0008] The second object of the present invention is to provide the use of the above-mentioned small molecule substance in the preparation of products of peptidyl arginine deiminase 4 inhibitors.

[0009] The third object of the present invention is to provide the use of the above-mentioned small molecule substance in the preparation of a drug for treating or preventing a disease mediated by peptidyl arginine deiminase 4.

[0010] The fourth object of the present invention is to provide the use of the above-mentioned small molecule substance in inhibiting the formation of neutrophil extracellular traps, or in the preparation of a product for inhibiting the formation of neutrophil extracellular traps.

[0011] The fifth object of the present invention is to provide the use of the above-mentioned small molecule substance in the preparation of a drug for preventing or treating diseases related to neutrophil extracellular traps.

[0012] The sixth object of the present invention is to provide a peptidyl arginine deiminase 4 inhibitor.

[0013] The seventh object of the present invention is to provide a drug for treating ulcerative colitis-related tumors.

[0014] The above-mentioned purpose of the present invention is achieved through the following technical solutions:

[0015] The PAD4 enzyme activity screening experiment of the present invention shows that glycyrrhizic acid, wogonin, and quercetin have an inhibitory effect on PAD4 activity. SPR interaction instrument and protein immunoblotting experiments further prove that glycyrrhizic acid can inhibit PAD4 enzyme activity. At the same time, cell model and animal model experiments prove that glycyrrhizic acid can inhibit cells from forming NETs and reduce the aggregation of NETs in the colon of model mice, thereby achieving the effect of treating colitis-related tumors. Therefore, glycyrrhizic acid, quercetin, and wogonin can be used as peptidyl arginine deiminase 4 inhibitors, and peptidyl arginine deiminase 4 inhibitors can be used for disease treatment purposes, and can also be used for non-disease treatment purposes, such as the application of PAD4 inhibitors in regulating the immunity of tumor mouse models in scientific research.

[0016] Therefore, the present invention provides the following application scheme:

[0017] The application of small molecule substances as peptidyl arginine deiminase 4 inhibitors, wherein the small molecule substances are one or a combination of glycyrrhizic acid, quercetin and wogonin.

[0018] Application of small molecule substances in the preparation of products of peptidyl arginine deiminase 4 inhibitors, wherein the small molecule substances are one or a combination of glycyrrhizic acid, quercetin and wogonin.

[0019] The invention relates to the use of small molecule substances in the preparation of drugs for treating or preventing diseases mediated by peptidyl arginine deiminase 4, wherein the small molecule substances are one or a combination of glycyrrhizic acid, quercetin and wogonin.

[0020] Specifically, diseases mediated by peptidyl arginine deiminase 4 include rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, cystic fibrosis, chronic obstructive pulmonary disease, and ulcerative colitis-associated tumors.

[0021] Application of small molecule substances in inhibiting the formation of neutrophil extracellular traps, wherein the small molecule substances are one or a combination of glycyrrhizic acid, quercetin and wogonin.

[0022] The invention discloses an application of a small molecule substance in preparing a product for inhibiting the formation of neutrophil extracellular traps, wherein the small molecule substance is one or a combination of glycyrrhizic acid, quercetin and wogonin.

[0023] The invention discloses an application of a small molecule substance in the preparation of a drug for preventing or treating diseases related to neutrophil extracellular traps, wherein the small molecule substance is one or a combination of glycyrrhizic acid, quercetin and wogonin.

[0024] Specifically, the neutrophil extracellular trap-related diseases include sepsis, acute respiratory distress syndrome, pulmonary fibrosis, pulmonary embolism, systemic lupus erythematosus, chronic obstructive pulmonary disease and ulcerative colitis-related tumors.

[0025] In addition, the present invention provides a peptidyl arginine deiminase 4 inhibitor, which contains one or more of glycyrrhizic acid, wogonin, and quercetin.

[0026] As an optional embodiment, the peptidyl arginine deiminase 4 inhibitor further contains a pharmaceutically acceptable carrier.

[0027] As an alternative embodiment, the carrier comprises a liposome, a micelle, a dendrimer, a microsphere or a microcapsule.

[0028] The invention provides an ulcerative colitis-related tumor drug, which contains one or more of glycyrrhizic acid, wogonin and quercetin.

[0029] As an optional embodiment, the ulcerative colitis-related tumor drug further contains a drug adjuvant.

[0030] As an optional embodiment, the pharmaceutical adjuvant includes one or more of a diluent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an emulsifier, a solubilizer, a solubilizing agent, a pH regulator, an antioxidant, and an antibacterial agent.

[0031] The present invention has the following beneficial effects:

[0032] The experimental studies of the present invention show that glycyrrhizic acid, baicalin and quercetin have an inhibitory effect on the activity of PAD4 enzyme, and further prove through cell model and animal model experiments that glycyrrhizic acid can inhibit the formation of NETs by cells, inhibit the expression of PAD4 in the colon tissue of model mice, and reduce the aggregation of NETs in the colon tissue, thereby achieving the effect of treating colitis-related tumors.

[0033] In addition, glycyrrhizic acid, quercetin, and wogonin are all small molecules derived from safe plants. Among them, glycyrrhizic acid has been widely used as a sweetener and flavoring in various foods. It has no obvious toxic effects on the environment, human body, and plants, and is highly safe. Moreover, compared with most peptide-based PAD inhibitors, small molecule inhibitors have better cell permeability and stability. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 Prediction of the affinity of different small molecule compounds to PAD4 (Figure A is the prediction of the affinity of different small molecule compounds to PAD4; Figure B is the display of the PAD4 enzyme active site; Figure C is the effect of different small molecule compounds on the PAD4 enzyme activity).

[0035] Figure 2 These are the prediction results of the binding between baicalin, quercetin, and glycyrrhizic acid and PAD4 (Figure A is the prediction result of the binding between quercetin and PAD4; Figure B is the prediction result of the binding between baicalin and PAD4; Figure C is the prediction result of the binding between glycyrrhizic acid and PAD4; Figure D is the prediction result of the binding between GSK484 and PAD4).

[0036] Figure 3 These are the results of in vitro analysis of the interaction between glycyrrhizic acid and PAD4.

[0037] Figure 4 The effect of glycyrrhizic acid on the in vitro enzyme activity of PAD4 (N represents the normal group; compared with the N group, *P<0.05, **P<0.01).

[0038] Figure 5The effect of glycyrrhizic acid on phorbol ester-stimulated cell model (Figure A shows the microscopic observation results of cells treated with different methods; Figure B shows the electron microscopic observation results of cells treated with different methods; Figure C shows the expression level results of NE and CitH3 observed by immunofluorescence staining).

[0039] Figure 6 The results of MPO-DNA content detection in the culture supernatant of cells with different treatments (compared with group M, *P<0.05, **P<0.01; compared with group N, ##P<0.01).

[0040] Figure 7 The effect of glycyrrhizic acid on the ulcerative colitis-related tumor mouse model (Figure A shows the immunofluorescence detection results of intestinal NETs in mice with different treatments; Figure B shows the immunohistochemical detection results of PAD4 expression in colon tissues of mice with different treatments).

[0041] Figure 8 The results of ELISA detection of MPO-DNA complex in colon tissue homogenates of mice treated with different methods (compared with group M, *P<0.05, **P<0.01; compared with group N, ##P<0.01, ###P<0.001). DETAILED DESCRIPTION

[0042] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0043] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0044] (1) The sources of specific reagents in the examples are shown in Table 1. Antibodies were diluted with TBST solution according to their instructions before use.

[0045] Table 1 Sources of reagents

[0046]

[0047]

[0048] (2) Preparation of reagents PBS buffer: Take a packet of PBS buffer according to the instructions, add distilled water to make up to 2 L, and adjust the pH to 7.2-7.4 after fully dissolving.

[0049] TBST solution: Take a packet of TBS powder, dilute to 2L with ultrapure water, fully dissolve, and add 2mL Tween 20.

[0050] 1× Electrophoresis buffer: Weigh 3.02 g of Tris-base, 18.8 g of Glycine, and 1 g of SDS, add ultrapure water to make up to 1 L, and store at 4 °C for later use.

[0051] 1× Transfer buffer: Weigh 3.3 g of Tris-base, 14.4 g of Glycine, and 0.1 g of SDS, add ultrapure water to make up to 800 mL and dissolve thoroughly, then add methanol to make up to 1 L, and store at 4 °C for later use.

[0052] Normal saline: Weigh 0.9056 g of NaCl precisely and dissolve it in 50 mL of ultrapure water, make up to 100 mL, sterilize it in an autoclave, and store it at 4 °C after cooling.

[0053] 1 mg / mL Azoxymethane (AOM) solution: Take 20 μL of AOM stock solution (containing 25 mg), add 25 mL of normal saline for dilution, and store at -20 °C for later use.

[0054] 2% Dextran sulfate sodium (DSS) solution: Weigh 40.0101 g of DSS powder precisely, add 2 L of pure water (RO water) and stir until completely dissolved, and store at 4 °C for later use.

[0055] 10 mg / mL Aspirin suspension: Weigh 1 enteric-coated aspirin tablet (containing 100 mg), add 10 mL of pure water (RO water) and grind it, take the supernatant, and store at 4 °C for later use.

[0056] Glycyrrhizic acid solutions (1.5 mg / mL, 1 mg / mL, 0.5 mg / mL): Take 20 mg of glycyrrhizic acid powder, dissolve it in 10 mL of pure water (RO water) to obtain a 2 mg / mL stock solution. Then, take 4.5 mL of the stock solution and add 1.5 mL of RO water for dilution to obtain the high-dose group solution (1.5 mg / mL), take 3 mL of the stock solution and add 3 mL of RO water for dilution to obtain the medium-dose group solution (1 mg / mL), and take 1.5 mL of the stock solution and add 4.5 mL of RO water for dilution to obtain the low-dose group solution (0.5 mg / mL).

[0057] (3) Experimental animals

[0058] Purchase 84 8-week-old SPF-grade C57BL / 6 mice (male, body weight 21 ± 2 g) from Guangdong Vital River Laboratory Animal Technology Co., Ltd. (Animal certificate number: 44829700001734). Purchase 60 8-week-old SPF-grade C57BL / 6 mice (male, body weight 21 ± 2 g) from Guangdong Laboratory Animal Center (Animal certificate number: 440072200109073). The mice are raised in the Experimental Animal Center on the fourth floor of the School of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine. Unit use permit: SYXK(Guangdong)2019 0202.

[0059] Example 1 Prediction of affinity between different small molecule compounds and PAD4 and screening of their activity

[0060] 1. Affinity prediction experiment

[0061] The PDB model of the receptor protein PAD4 was downloaded from the RCSB PDB database, and the 3D structure SDF files of baicalein, wogonin, wogonoside, quercetin, glycyrrhizic acid and PAD4 inhibitor GSK484 were downloaded from the PubChem database. AutoDock Vina software was used to perform docking simulation on baicalein, wogonin, wogonoside, quercetin, glycyrrhizic acid and GSK484 after binding to calcium ions with the PAD4 protein molecule to predict the affinity of PAD4 with different small molecule compounds.

[0062] Experimental results: PAD4 enzyme active site Figure 1 As shown in Figure B, the affinity predictions of different small molecule compounds to PAD4 are as follows Figure 1 As shown in Figure A, the results show that the affinity of glycyrrhizic acid to PAD4 is the highest among the five compounds and is higher than that of the PAD4 inhibitor GSK484.

[0063] 2. In vitro screening of PAD4 enzyme activity inhibitors

[0064] The PAD4 inhibitor screening test kit (Cayman Chemical) was used to detect the inhibitory effects of baicalin, wogonin, quercetin, and glycyrrhizic acid on PAD4. The positive control was the PAD4 inhibitor Cl-amidine.

[0065] The detection method was carried out according to the kit instructions, specifically:

[0066] ① Set up 100% initial activity wells, background wells, inhibitor wells, and positive control wells for processing;

[0067] 100% initial activity wells: add 20 μL of diluted PAD4 detection reagent (AMC) and 5 μL of solvent (the same solvent used to dissolve the inhibitor) to 3 wells of a 96-well plate;

[0068] Background wells: 20 μL of PAD assay buffer and 5 μL of solvent (the same solvent in which the solubilization inhibitor was dissolved) were added to 3 wells of a 96-well plate;

[0069] Inhibitor wells: Add 20 μL of diluted PAD4 assay reagent and 5 μL of inhibitor to 3 wells of a 96-well plate; (the inhibitor can be dissolved in PAD assay buffer, ≤20% methanol, ≤10% ethanol, or ≤10% DMSO and should be added to the assay in a volume of 5 μL);

[0070] Positive Control Wells: Add 20 μL of diluted PAD4 Detection Reagent and 5 μL of reconstituted Chlor-Amine Inhibitor Detection Reagent to 3 wells of a 96-well plate.

[0071] ② Cover the plate with a plate cover and incubate at 37°C for 10 minutes. Remove the plate cover and add 25 μL of diluted PAD detection substrate to all used wells.

[0072] ③ Cover the plate with a plate cover and incubate at 37°C for 20 min; remove the plate cover and add 50 μL of PAD developer (ECL chemiluminescent liquid) to all wells used; cover the plate with a plate cover and incubate at room temperature for 10 min.

[0073] ④ Remove the plate cover and read the fluorescence at an excitation wavelength of 355-365 nm and an emission wavelength of 445-455 nm.

[0074] ⑤ Determine the average fluorescence of the background wells (BW), 100% initial activity wells (IA), positive control wells (PC inhibitor) and inhibitor wells.

[0075] The PAD4 enzyme activity of the negative control was expressed as the absolute value of the average fluorescence value of the 100% initial activity well minus the average fluorescence value of the background well; the PAD4 enzyme activity of the inhibitor well was expressed as the absolute value of the average fluorescence value of the inhibitor well minus the average fluorescence value of the background well.

[0076] Experimental results: The effects of different small molecule compounds on PAD4 enzyme activity are shown in Figure 1 As shown in Figure C, the results show that glycyrrhizic acid is significantly better than baicalin in inhibiting the enzyme activity of PAD4, slightly better than wogonin and quercetin, and is comparable to the positive control Cl-amidine in inhibiting the enzyme activity of PAD4.

[0077] Example 2 Prediction of the binding of baicalin, quercetin, glycyrrhizic acid and PAD4

[0078] 1. Experimental Methods

[0079] The top three small molecule compounds with the highest affinity, baicalin, quercetin and glycyrrhizic acid, were selected based on the molecular docking simulation results in Example 1. The interaction between baicalin, quercetin, glycyrrhizic acid and PAD4 protein was analyzed using the PLIP online analysis website, with GSK484 as a control.

[0080] 2. Experimental Results

[0081] The prediction results of the binding of baicalin, quercetin, glycyrrhizic acid and PAD4 are as follows Figure 2 As shown, the results show that:

[0082] Quercetin may bind to ASN-648, ASN-588, MET-352, GLU-353, GLY-408, ASP-473, GLU-411, and HIS-471 amino acids of PAD4 ( Figure 2 Figure A).

[0083] Baicalein may bind to ASN-301, ARG-651, SN-648, and GLU-353 amino acids of PAD4 ( Figure 2 Figure B).

[0084] Glycyrrhizic acid may bind to CYS-645, THR-647, ALA-581, ASP-350, ASP-473, GLU-580, GLY408, and HIS-471 amino acids of PAD4, among which CYS-645, ASP-350, ASP-473, and HIS-471 are the active clefts of PAD4 ( Figure 2 Figure C).

[0085] GSK484 has the potential to bind to the ASN-588 amino acid of PAD4 ( Figure 2 Figure D).

[0086] Example 3 Analysis of the binding effect of glycyrrhizic acid on PAD4 in vitro

[0087] 1. Experimental Methods

[0088] (1) Install the NTA chip according to the standard operating procedure of the SPR instrument. The instrument was first operated at the maximum flow rate (150 μL / min) to detect the basic signal of the buffer PBS (pH 7.4). After the signal baseline was stable, the flow rate of the buffer was adjusted to 20 μL / min.

[0089] (2) Activate the detection chip, take out the prepared imidazole and NiCl2 solutions, and inject them through the injection port to complete the functionalization of the chip surface and prepare to fix the ligand (PAD4) with a his tag.

[0090] (3) Dissolve 50 μg of PAD4 recombinant protein in 200 μL PBS and load it at a flow rate of 20 μL / min. The binding time is 4 minutes and the baseline is observed for 5 minutes to ensure stability.

[0091] (4) After the ligand signal stabilized, high concentration of glycyrrhizic acid (800 μM) was injected to confirm the activity of the ligand and the approximate maximum binding capacity of the PAD4 surface.

[0092] (5) The flow rate was increased to 150 μL / min, and 50 mL of regeneration buffer (10 mM glycine hydrochloride solution, pH 1.5) was injected to remove the analyte glycyrrhizic acid. Glycyrrhizic acid was diluted to 400, 200, and 100 μM concentrations with PBS (pH 7.4) containing 1% DMSO and loaded at 20 μL / min. The protein-ligand binding time was 240 s and the natural dissociation time was 260 s.

[0093] (6) The experimental results were analyzed using the TraceDrawer (Ridgeview Instrumentsab, Sweden) analysis software for a One To One model.

[0094] 2. Experimental Results

[0095] The affinity constant between glycyrrhizic acid and human PAD4 recombinant protein was detected by SPR interaction instrument.

[0096] The results of the in vitro interaction analysis between glycyrrhizic acid and PAD4 are shown in Figure 3 As shown in Table 2, the results showed that the RU values ​​of glycyrrhizic acid and PAD4 were positively correlated with the dose. One To One model analysis using TraceDrawer software showed that the binding rate constant ka of glycyrrhizic acid and PAD4 was 1.40e1 (1 / (M*s)), the dissociation rate constant kd was 1.09e-2 (1 / s), and the affinity constant KD was 7.77e-4M.

[0097] Table 2 Kinetic constants of PAD4 and glycyrrhizic acid

[0098]

[0099] Example 4 Effect of glycyrrhizic acid on PAD4 enzyme activity in vitro

[0100] 1. Experimental Methods

[0101] The PAD4 reaction substrate is mainly histone Histone3, and it induces its citrullination. In this example, dHL-60 cell protein was extracted and incubated with glycyrrhizic acid and PAD4 inhibitor GSK484. 2+ After ion activation, the content of the product CitH3 is detected. The specific experimental method is as follows:

[0102] (1) In vitro culture of HL-60 cells

[0103] In vitro culture: Human promyelocytic leukemia cell line HL-60 cells were cultured in complete culture medium (PRMI-1640 culture medium containing 1% double antibody and 10% fetal bovine serum) and placed in a cell culture incubator at 37°C and 5% CO2 for culture. The culture medium was centrifuged at low speed (4°C, 200g for 4 min), and fresh complete culture medium was added for resuspending for culture and subculture.

[0104] Inducing differentiation: Take HL-60 cells in the logarithmic growth phase, centrifuge and adjust the cell concentration to 5-8×10 5 Take a 6-well cell culture plate, add 1 mL of cell suspension to each well, and add 2 μM retinoic acid to stimulate for 4 days (replace new complete culture medium on the second day) and collect the cells to obtain dHL-60 cells.

[0105] (2) Protein extraction and reaction

[0106] Collect stimulated cells in 1.5mL EP tubes, centrifuge at 4℃, 500g for 5min, and discard the supernatant. Add 1mL PBS to wash, centrifuge at 4℃, 700g for 5min, and discard the supernatant. Invert the EP tube on the filter paper to absorb the remaining PBS solution, add 40μL cell lysis buffer (containing 1% phenylmethylsulfonyl fluoride PMSF, without EDTA), vortex for 30s, and lyse on ice for 10min. Add different doses of glycyrrhizic acid (20, 40, 60μM) and 20μM GSK484, vortex for 10s, and react at room temperature for 20min. Add 2mM CaCl2 to the constant temperature shaker at 37℃ for 25min, and after low-temperature ultrasound for 5min, centrifuge at 4℃, 14000g for 10min, collect the supernatant, and store at -80℃ for use. The protein extracted by incubation without adding glycyrrhizic acid and GSK484 was used as the normal group (N).

[0107] (3) Protein concentration detection and denaturation

[0108] Use the BCA protein concentration determination kit (Biyuntian) to determine the concentration of the protein sample according to the kit instructions. The specific method is as follows:

[0109] Take 0.5μg / μL protein standard for dilution, set 8 concentration gradients of 0.5, 0.4, 0.3, 0.2, 0.1, 0.05, 0.025, and 0μg / μL, and take 20μL to the corresponding wells; add 1μL sample to the sample well and make up to 20μL with PBS; add 200μL of the prepared working solution (A solution: B solution = 50:1) to each well, incubate in a 37℃ constant temperature box for 20min; use an enzyme reader to measure the absorbance at 562nm, and calculate the protein concentration of the sample according to the standard curve and the dilution multiple of the sample.

[0110] Vortex mix at a ratio of 5× protein loading buffer: sample = 1: 4. Denature the sample suspension in a 100°C metal bath for 6 min, cool on ice, centrifuge and vortex, and store at -80°C for later use.

[0111] (4) SDS-PAGE gel electrophoresis: Prepare 12% separation gel and 5% concentration gel according to the gel preparation instructions of the SDS-PAGE rapid gel preparation kit, and add them between the two plates in sequence. Quickly insert the comb and let it stand at room temperature for 30 minutes until the gel solidifies. After the gel preparation is completed, install the electrophoresis device, pour in the electrophoresis buffer, and pull out the comb. Add 4μL of protein marker to each side, and load the sample wells in sequence according to the total amount of 20μg protein. The samples are electrophoresed at 120V for 90 minutes.

[0112] (5) Transfer: After the electrophoresis is completed, install the transfer device, soak the (0.22 μm) PVDF membrane in methanol for 5 seconds, clamp it in a "sandwich" arrangement, and avoid the generation of bubbles in the "sandwich". Transfer the membrane to an ice box at 100 V for 100 min.

[0113] (6) Nonspecific blocking: After transfer, the PVDF membrane was washed with TBST for 3 min and blocked with 5% skim milk powder (dissolved in TBST) at room temperature for 1.5 h.

[0114] (7) Incubation with target antibody: Recover the blocking solution, wash with TBST for 5 min, cut the corresponding bands according to the protein molecular weight, add Rabbit anti human CitH3 antibody and Mouse anti mouse β-Actin antibody respectively, incubate at 4°C overnight, and prepare the antibody with 5% skim milk powder. The next day, remove the PVDF membrane, warm it up for 20 min, wash it with TBST (8 min × 3 times), add goat anti-rabbit and goat anti-mouse secondary antibodies respectively, incubate at room temperature for 1 h, and wash it with TBST for 8 min × 3.

[0115] (8) Luminescence color development: After the front side of the membrane is completely in contact with the ECL chemiluminescent solution for 20 seconds, the chemiluminescence instrument is used to expose and photograph the results, and the protein grayscale value is calculated using image J software.

[0116] 2. Experimental Results

[0117] The results of the effect of glycyrrhizic acid on the in vitro enzyme activity of PAD4 are as follows Figure 4 As shown, the results showed that glycyrrhizic acid could reduce the enzyme activity of PAD4 in a dose-dependent manner, and the inhibitory effect of high doses was similar to that of the positive drug GSK484.

[0118] Example 5 Glycyrrhizic acid inhibits PMA-induced HL-60 from forming NETs

[0119] This example mainly uses phorbol ester (PMA) to induce NETs in vitro model, and simultaneously administers different doses of glycyrrhizic acid for treatment. The experiment investigates the effect of glycyrrhizic acid on neutrophil NETs formation in vitro from multiple aspects, including NETs-related components, NETs microstructure, and damage function.

[0120] 1. Experimental Methods

[0121] (1) Establishment of in vitro drug intervention model of neutrophil NETs

[0122] Treatment groups (different drugs): HL-60 cells in the exponential growth phase were stimulated with 2 μM retinoic acid for 4 days, and the cell concentration was adjusted to 1×10 6 / mL, 20μM, 40μM, and 60μM glycyrrhizic acid were added respectively, and 20μM GSK484 was incubated for 30min, and then 40ng / mL PMA was added to stimulate for 4 hours.

[0123] Normal culture group (N): HL-60 cells in the exponential growth phase were stimulated with 2 μM retinoic acid for 4 days, and the cell concentration was adjusted to 1×10 6 Pieces / mL.

[0124] Model group (M): HL-60 cells in the exponential growth phase were stimulated with 2 μM retinoic acid for 4 days, and the cell concentration was adjusted to 1×10 6 / mL, and PMA at a concentration of 40ng / mL was added for stimulation for 4 hours.

[0125] (2) Scanning electron microscopy and immunofluorescence detection of NETs structure

[0126] Specific method for detecting NETs structure by scanning electron microscopy:

[0127] ① Collect the cell suspensions with different treatments (the amount of cells required for 12 wells), add 1 mL PBS to rinse the bottom cells, collect the PBS rinse solution, combine the collected cell suspension and PBS rinse solution, centrifuge at 300g for 4 minutes, and discard the supernatant; add 1 mL PBS to wash, centrifuge, and discard the supernatant. Add 2 mL of electron microscopy fixative and fix at room temperature for 2 hours, then transfer to 4°C for storage.

[0128] ② Post-fixation: The fixed samples were rinsed with PBS for 3 times, 15 minutes each time. 1% osmium acid was prepared with 0.1M phosphate buffer (pH 7.4), and the samples were fixed with 1% osmium acid at room temperature in the dark for 1-2 hours. Then rinsed with PBS for 3 times, 15 minutes each time.

[0129] ③ Dehydration: The samples were dehydrated (immersed) once with ethanol solutions of gradient concentrations (including 7 concentrations: 30%, 50%, 70%, 80%, 90%, 95%, and 100%), each treatment lasting 15 minutes, and then immersed in isoamyl acetate for 15 minutes.

[0130] ④ Drying: Place the sample in a critical point dryer for drying.

[0131] ⑤ Conductive treatment of samples: Place the sample tightly onto the conductive carbon film double-sided tape and place it on the sample stage of the ion sputtering instrument for gold spraying for about 30 seconds.

[0132] ⑥Observe the samples using a scanning electron microscope.

[0133] Specific method for immunofluorescence detection of NETs structure:

[0134] ① Collect the cell suspensions with different treatments, add 1 mL of PBS to rinse the bottom cells, collect the PBS rinse solution, combine the collected cell suspension and PBS rinse solution, centrifuge at 300g for 4 minutes, and discard the supernatant. Add 1 mL of PBS to wash, centrifuge, discard the supernatant, and then add 500 μL of PBS to resuspend to obtain a cell resuspension.

[0135] ② Use an immunohistochemistry pen to draw a circle with a diameter of about 1 cm on the adsorption slide, take 30 μL of cell resuspension and evenly apply it in the circle, and bake in a 50℃ oven for 10 minutes.

[0136] ③Fix with pre-cooled acetone on ice for 20 minutes, wash with PBS (5 minutes × 3 times). Add 50 μL of 0.3% Triton-X-100 solution, permeabilize at room temperature for 30 minutes, then soak and wash with PBS (5 minutes × 3 times), add 50 μL of 1% bovine serum albumin solution (BSA), and block at room temperature for 30 minutes.

[0137] ④ Add Rabbit anti CitH3 antibody and Rabbit anti NE antibody, incubate at 4°C overnight, and wash with PBS (5 min × 3 times). Add goat anti-rabbit-Cy3 and goat anti-mouse-FITC, and incubate at room temperature for 1 hour.

[0138] ⑤ Soak and wash with PBS (5 min × 3 times), remove the residual PBS with filter paper, seal the slides with a fluorescence anti-quencher containing 4',6-diamidino-2-phenylindole (DAPI), and observe and take pictures under a fluorescence microscope.

[0139] (3) ELISA detection of the content of MPO-DNA complex in cell supernatant

[0140] The cell suspensions of the different drug treatment groups, normal culture group and model group of this example were collected, and the culture supernatants were obtained by centrifugation. The mouse myeloperoxidase-DNA complex (MPO-DNA) ELISA research kit (Jiangsu Enzyme Immunity Industrial Co., Ltd.) was used to detect the MPO-DNA content in the culture supernatant.

[0141] 2. Experimental Results

[0142] The microscopic and scanning electron microscopic observation results of cells treated with different methods are shown in Figure 2. Figure 5 As shown in Figures A and B, the results show that after PMA induction stimulation, the color of dHL-60 cells in the model group became darker than that of the normal group cells, and the morphology changed from spherical to spindle-shaped, accompanied by the rupture of the cell membrane. Scanning electron microscopy results also showed that the cell membrane of the cells in the model group ruptured and the contents were released, indicating that NETs were formed in the dHL-60 cells in the model group, and glycyrrhizic acid could reduce the number of such cells.

[0143] The results of immunofluorescence labeling of citrullinated histone (CitH3) and neutrophil elastase (NE) are shown in Figure 5 As shown in Figure C, the results showed that PAD4 mediated the formation of NETs, ​​and glycyrrhizic acid could inhibit PMA-induced NETs formation by inhibiting PAD4.

[0144] The results of MPO-DNA content detection in the culture supernatant of cells with different treatments are as follows Figure 6 As shown, the results showed that glycyrrhizic acid could reduce the production of MPO-DNA complex, a marker of NETs.

[0145] Example 6 Glycyrrhizic acid reduces the aggregation of NETS in the mouse colon

[0146] 1. Experimental Methods

[0147] (1) Establishment of ulcerative colitis-related tumor mouse model and drug intervention mouse modeling

[0148] In this study, a mouse model of ulcerative colitis-related tumors was established by co-induction of 2% DSS solution and AOM solution (10 mg / kg). Sixty 8-week-old SPF-grade C57BL / 6 mice (male, weighing 21±2 g) were intraperitoneally injected with 1 mg / mL AOM solution (10 mg / kg) at a dosage of 0.1 mL / 10 g. After 72 hours, three rounds of dextran sulfate sodium (DSS) stimulation were performed (one round of DSS stimulation was based on mice freely drinking 2% DSS solution for one week and freely drinking sterile distilled water for 2 weeks).

[0149] In the third week, the surviving mice were randomly divided into 6 groups according to body weight groups, including model group (M group), aspirin control group (40 mg / kg), low-, medium- and high-dose glycyrrhizic acid groups (10, 20, 30 mg / kg), and GSK484 control group (2 mg / kg), with 10 mice in each group.

[0150] Model group (AOM / DSS): mice induced with a combination of 2% DSS solution and AOM solution (10 mg / kg), namely, mice with colitis-related tumors.

[0151] Aspirin control group: Each model mouse was intraperitoneally injected with aspirin suspension at a dose of 40 mg / kg.

[0152] Low-dose glycyrrhizic acid group: Each model mouse was intraperitoneally injected with glycyrrhizic acid solution at a dose of 10 mg / kg.

[0153] Medium-dose glycyrrhizic acid group: Each model mouse was intraperitoneally injected with glycyrrhizic acid solution at a dose of 20 mg / kg.

[0154] Glycyrrhizic acid high-dose group: Each model mouse was intraperitoneally injected with glycyrrhizic acid solution at a dose of 30 mg / kg.

[0155] GSK484 control group: Each model mouse was intraperitoneally injected with GSK484 solution at a dose of 2 mg / kg.

[0156] The mice were given aspirin suspension, GSK484 solution, and glycyrrhizic acid solution at different doses, and intraperitoneally injected every two days. At the same time, normally cultured mice (N group) were set up as a control group (10 mice). After the ninth week, samples were collected for testing of various indicators.

[0157] (2) Immunofluorescence detection of CitH3 and MPO expression in tissues

[0158] The whole intestinal tissue was fixed with 10% paraformaldehyde for 24 hours, embedded in paraffin, and sliced. Tissue dewaxing, tissue antigen repair, tissue permeabilization, and surface nonspecific antigen blocking were performed according to the fixation method for immunohistochemical detection. The specific method is as follows:

[0159] ① Incubation with target antibody: remove the blocking solution, add 40μL of Rabbit anti CitH3 and 40μL of Anti-h / mMPO antibody respectively, and incubate overnight at 4℃ in an immunohistochemical humidified box; take out the slices on the next day, soak and wash the tissue with PBS (5min×3 times), add donkey anti-rabbit IgG antibody, and incubate in an immunohistochemical humidified box at room temperature for 1h.

[0160] ②DAPI sealing: Take out the slices, soak and wash the tissue with PBS (5min×3 times), absorb the residual PBS with filter paper, seal the slices with fluorescence anti-quenching agent containing DAPI, and observe and take pictures under fluorescence microscope.

[0161] (3) Immunohistochemical detection of PAD4 expression in tissues

[0162] The whole colon tissue was fixed with 10% paraformaldehyde for 24 h, embedded in paraffin, and sliced. Immunohistochemical detection was performed according to the following protocol:

[0163] ① Perform tissue dewaxing, tissue antigen repair, inhibition of endogenous enzyme activity and surface nonspecific antigen blocking according to the fixation method;

[0164] ② Incubation with target antibody: remove the blocking solution, add 40 μL of Rabbit anti PAD4 antibody, and incubate overnight at 4°C in an immunohistochemical humidified box; take out the sections the next day, soak and wash the tissues with PBS (5 min × 3 times), add goat anti-rabbit IgG antibody (secondary antibody), and incubate in an immunohistochemical humidified box at room temperature for 1 hour.

[0165] ③Diaminobenzidine (DAB) staining: Wash the tissue by soaking in TBST (5 min × 3 times), add 40 μL 1×DAB working solution (DAB color development kit), stain at room temperature for 60 s, and immediately soak in ultrapure water for 5 min.

[0166] ④Hematoxylin restaining: Take out the slices, add hematoxylin staining solution, stain at room temperature for 20 seconds, and then wash with tap water for 5 minutes.

[0167] ⑤ Dehydration and sealing: Take out the slices and dehydrate them with different concentrations of ethanol (absolute ethanol, 95% ethanol, 90% ethanol, 80% ethanol, 70% ethanol, 5 minutes each time) and TO-type biological slide transparent agent (10 minutes × 3 times). Use neutral gum to seal the slides and observe and take pictures under a microscope.

[0168] (4) ELISA detection of MPO-DNA expression in tissue homogenate

[0169] The frozen -80°C tissue homogenate was taken out and rewarmed at room temperature for 15 min. At the same time, the mouse myeloperoxidase-DNA complex (MPO-DNA) ELISA research kit (Jiangsu Enzyme Immunity Industrial Co., Ltd.) was used to detect the MPO-DNA content of the tissue homogenate according to the instructions.

[0170] 2. Experimental Results

[0171] Neutrophils can aggravate intestinal inflammatory damage by forming NETs. The immunofluorescence detection results of intestinal NETs in mice with different treatments are shown in Figure 2. Figure 7As shown in Figure A, the results showed that NETs accumulated in large quantities in the intestines of mice with colitis-related tumors induced by DSS and AOM (model group). After intervention with glycyrrhizic acid and the PAD4 inhibitor GSK484, the expression levels of CitH3 and MPO tended to decrease, and the formation of NETs in the colon was inhibited.

[0172] The formation of NETs is closely related to its core protease PAD4. The results of immunohistochemical detection of PAD4 expression in colon tissues of mice treated with different methods are shown in Figure 2. Figure 7 As shown in Figure B, the results showed that PAD4 expression was significantly increased in the intestine of mice with colitis-associated tumors, while glycyrrhizic acid treatment could inhibit the expression of PAD4 in tissues.

[0173] NETs are a network complex composed of neutrophil active ingredients MPO, histones and DNA. The ELISA test results of MPO-DNA complexes in colon tissue homogenates of mice treated with different methods are shown in Figure 2. Figure 8 As shown, the results showed that the level of MPO-DNA complex, a NETs marker, in mice with colitis-associated tumors was higher than that in normal mice, and glycyrrhizic acid intervention could effectively reduce the level of this substance in tissue homogenate.

[0174] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. Use of a small molecule substance as a peptidyl arginine deiminase 4 inhibitor, wherein the small molecule substance is one or a combination of glycyrrhizic acid, quercetin, and wogonin.

2. Use of a small molecule substance in the preparation of a product of a peptidyl arginine deiminase 4 inhibitor, wherein the small molecule substance is one or a combination of glycyrrhizic acid, quercetin, and wogonin.

3. Use of a small molecule substance in the preparation of a drug for treating or preventing a disease mediated by peptidyl arginine deiminase 4, wherein the small molecule substance is one or a combination of glycyrrhizic acid, quercetin, and wogonin.

4. Application of small molecule substances in inhibiting the formation of neutrophil extracellular traps, wherein the small molecule substances are one or a combination of glycyrrhizic acid, quercetin, and wogonin.

5. Use of a small molecule substance in the preparation of a product for inhibiting the formation of neutrophil extracellular traps, wherein the small molecule substance is one or a combination of glycyrrhizic acid, quercetin, and wogonin.

6. Use of a small molecule substance in the preparation of a drug for preventing or treating a disease related to neutrophil extracellular traps, wherein the small molecule substance is one or a combination of glycyrrhizic acid, quercetin, and wogonin.

7. A peptidyl arginine deiminase 4 inhibitor, characterized in that: Contains one or more of glycyrrhizic acid, wogonin and quercetin.

8. The peptidyl arginine deiminase 4 inhibitor according to claim 7, characterized in that It also contains a pharmaceutically acceptable carrier.

9. The peptidyl arginine deiminase 4 inhibitor according to claim 8, characterized in that The carrier includes liposomes, micelles, dendrimers, microspheres or microcapsules.

10. A drug for treating ulcerative colitis-related tumors, characterized in that: Contains one or more of glycyrrhizic acid, wogonin and quercetin.